Search Orphan Drug Designations and Approvals
-
| Generic Name: | Amphotericin B lipid complex | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Name: | Abelcet | ||||||||||||||||
| Date Designated: | 12/05/1991 | ||||||||||||||||
| Orphan Designation: | Treatment of invasive fungal infections. | ||||||||||||||||
| Orphan Designation Status: | Designated/Approved | ||||||||||||||||
| Sponsor: |
Liposome Company, Inc. One Research Way Princeton, New Jersey 08540 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
| 1 | Generic Name: | Amphotericin B lipid complex |
|---|---|---|
| Trade Name: | Abelcet | |
| Marketing Approval Date: | 10/18/1996 | |
| Approved Labeled Indication: | Treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy. | |
| Exclusivity End Date: | 10/18/2003 | |
| Exclusivity Protected Indication* : | ||
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







